Managing Erectile Dysfunction in Heart Failure

Author(s): V. A. Giagulli, P. Moghetti, J. M. Kaufman, E. Guastamacchia, M. Iacoviello, V. Triggiani

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 13 , Issue 1 , 2013

Become EABM
Become Reviewer
Call for Editor


Nowadays, erectile dysfunction (ED) is considered an increasingly important clinical condition in men with heart failure (HF) which may influence the therapeutic approach to these patients. Since there is cogent evidence that ED is a “sentinel marker” of acute cardiovascular events especially in men younger than 65 years or in those affected by type 2 diabetes mellitus, it deserves an early diagnosis and an appropriate treatment.

In NYHA III-IV class HF patients, sexual activity could lead to acute cardiovascular events and this should be taken into account when approaching ED patients.

Moreover, it is well known that some classes of drugs, normally employed in the treatment of HF patients (e.g.thiazide diuretics, spironolactone and β-blockers), might worsen or even contribute to ED development. On the other hand, growing evidence suggests that PDE 5 inhibitors (vardenafil, tadalafil and sildenafil) seem to better satisfy the needs of NYHA HF I- II class men suffering from ED. In fact, they show few side effects, while improving both cardiopulmonary parameters and quality of life. Therefore, the aim of this review is to sum up the most recent evidence regarding the management of ED in men suffering from HF.

Keywords: Erectile dysfunction, Heart Failure, Phosphodiesterase type 5 (PDE 5) therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [125 - 134]
Pages: 10
DOI: 10.2174/1871530311313010015
Price: $65

Article Metrics

PDF: 65